Intrarosa and Apixaban Interaction: What Women with GSM Need to Know

What Is the Intrarosa-Apixaban Interaction, Exactly?

The short answer is that no well-controlled clinical trial has directly studied this drug pair in women. What we can do is work through the pharmacology of each drug, assess where their metabolic pathways overlap, and give you an honest picture of the theoretical versus the demonstrated risk.

Intrarosa is the brand name for prasterone 6.5 mg vaginal inserts, approved by the FDA in November 2016 for moderate-to-severe dyspareunia caused by genitourinary syndrome of menopause (GSM). Apixaban (Eliquis) is a direct oral anticoagulant (DOAC) that inhibits Factor Xa, used to prevent stroke in atrial fibrillation and to treat or prevent venous thromboembolism (VTE).

These two drugs are prescribed together more often than you might expect. GSM affects approximately 27 to 84 percent of postmenopausal women, and atrial fibrillation prevalence rises steeply after age 65. A woman in her late 60s or 70s managing painful sex alongside a heart arrhythmia is a real and common clinical picture.

How Apixaban Is Metabolized

Apixaban is metabolized primarily by CYP3A4 and, to a lesser degree, CYP1A2, and it is also a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). Strong inhibitors of CYP3A4 and P-gp combined (such as ketoconazole or ritonavir) can raise apixaban exposure by roughly 100 percent, which is why the FDA label for apixaban recommends a dose reduction for patients on such agents. Strong inducers (like rifampin) cut apixaban exposure and reduce anticoagulant effect.

This metabolic profile is why any drug that touches CYP3A4 or P-gp gets a close look when a patient is on apixaban.

How Prasterone (Vaginal DHEA) Is Metabolized

Prasterone is a synthetic form of dehydroepiandrosterone (DHEA), a naturally occurring adrenal steroid. Administered as a vaginal insert, it is converted locally in vaginal epithelial cells into estradiol and testosterone through intracrinology, meaning the conversion happens inside the target tissue rather than in the liver or blood. The FDA-approved labeling for Intrarosa reports that serum DHEA, estradiol, and testosterone levels after nightly vaginal administration remain within postmenopausal reference ranges.

DHEA itself is a substrate of multiple CYP enzymes including CYP3A4, CYP2C9, and CYP2C19, and it can act as a weak inducer or inhibitor of these pathways at higher concentrations. The word "weak" matters here. The systemic concentrations achieved with the 6.5 mg vaginal dose are far lower than those seen with oral DHEA supplementation, which means the magnitude of any CYP3A4 effect on apixaban pharmacokinetics is expected to be small.

The Mechanism: Where Do These Two Drugs Actually Overlap?

This framework maps the overlap between prasterone's metabolic footprint and apixaban's sensitivity to that footprint:

| Pathway | Apixaban role | Prasterone role | Clinical significance | |---|---|---|---| | CYP3A4 | Major substrate | Substrate; weak modulator at systemic concentrations | Theoretical; low magnitude expected | | P-glycoprotein (P-gp) | Substrate | Not a recognized P-gp inhibitor or inducer | No known interaction | | BCRP | Substrate | Not characterized as BCRP modulator | No known interaction | | Pharmacodynamic (bleeding) | Anticoagulant | No anticoagulant activity | No additive bleeding risk | | Estradiol effects on coagulation | None direct | Minimal systemic estradiol rise | Separate consideration below |

The pharmacodynamic picture is actually reassuring. Unlike systemic estrogen therapy, which can shift coagulation factor levels, the local intracrine conversion of prasterone produces estradiol levels that remain within the postmenopausal range. A 2016 phase 3 trial published in Menopause confirmed that serum hormone levels did not significantly exceed normal postmenopausal values after 12 weeks of nightly use. That matters because systemic estrogen, particularly oral combined hormonal contraceptives or high-dose oral estrogen therapy, carries a documented VTE risk, and that risk interacts with anticoagulant therapy in complex ways.

What DDI Databases Say

Major drug interaction databases (Drugs.com, Lexicomp, Micromedex) do not currently list prasterone vaginal as a clinically significant interactant with apixaban. The absence of a flagged interaction is not the same as proof of safety, and it partly reflects the limited pharmacokinetic data on vaginal DHEA at therapeutic doses in older women. The honest clinical position is: low theoretical risk, no documented harm, and a need for continued vigilance as post-marketing data accumulates.

GSM in Postmenopausal Women: Why This Drug Pair Comes Up

GSM is not a cosmetic concern. The 2020 ACOG Practice Bulletin on genitourinary syndrome of menopause describes it as a chronic, progressive condition affecting vulvovaginal tissue, the urethra, and bladder. Symptoms include vaginal dryness, burning, irritation, and dyspareunia. Unlike vasomotor symptoms, GSM does not improve without treatment.

Postmenopausal women with atrial fibrillation or a history of VTE are often told to avoid systemic hormone therapy. That leaves them with fewer options for GSM. Intrarosa offers local hormone activity without meaningful systemic exposure, which is exactly why it has appeal for women on anticoagulants.

Why Women on Anticoagulants Deserve Better Data

The data gap here is real and worth naming. Women have been systematically underrepresented in DOAC trials. The ARISTOTLE trial of apixaban, which enrolled over 18,000 patients, included only about 35 percent women. Female-specific pharmacokinetic data for apixaban shows that women tend to have slightly higher drug exposure than men at the same dose, a difference attributed to lower body weight and differences in renal clearance, but the clinical impact of this on interaction risk with vaginal hormonal agents has not been studied.

The prasterone trials were conducted almost exclusively in postmenopausal women, which is appropriate, but they were designed to study efficacy for dyspareunia, not pharmacokinetic interactions with anticoagulants. That leaves a real evidence gap that clinicians are navigating without direct data.

Estrogen, Coagulation, and Why Vaginal Route Matters

Oral and transdermal estrogen have different effects on coagulation. Oral estrogen, through first-pass hepatic metabolism, increases production of clotting factors and suppresses natural anticoagulant proteins, contributing to a measurable rise in VTE risk. Transdermal estrogen bypasses the liver and does not carry the same coagulation risk, a distinction confirmed in the E3N cohort study.

Vaginal prasterone sits even further along the spectrum toward no systemic effect. Because the hormone conversion is intracrine, the systemic estradiol exposure is minimal. Women on anticoagulants for VTE or atrial fibrillation should understand that prasterone does not add the kind of procoagulant burden that oral estrogen does. This does not eliminate the need for clinical review, but it does place the drug in a meaningfully different risk category than oral combined contraceptives or high-dose oral estrogen.

Pregnancy, Lactation, and Contraception

Prasterone vaginal (Intrarosa) is not indicated in premenopausal women and is contraindicated in pregnancy.

This section is included because every drug article on WomanRx addresses pregnancy and lactation safety, and because some women encounter Intrarosa prescribed off-label.

Pregnancy

The FDA label for Intrarosa carries no pregnancy category under the current Pregnancy and Lactation Labeling Rule (PLLR), because the drug is not indicated in pregnant women. Animal reproductive toxicity data have not been formally published for the vaginal formulation. DHEA is a naturally occurring steroid hormone, and exogenous administration during pregnancy raises theoretical concern about fetal androgen exposure, though no controlled human data exist. The product should not be used in pregnancy.

Apixaban carries a documented fetal bleeding risk. Animal studies show adverse reproductive effects, and it crosses the placenta in animal models. Apixaban should be discontinued before delivery and is not recommended in pregnancy. If a woman of reproductive age requires anticoagulation, low-molecular-weight heparin (LMWH) is the preferred agent during pregnancy.

Lactation

Prasterone vaginal: No human lactation data exist. Because the indication is GSM in postmenopausal women, no lactation studies have been conducted. Off-label use in a lactating woman would require individual risk-benefit discussion.

Apixaban: Apixaban is present in rat milk. Human lactation data are absent. Because of the potential for bleeding risk in a nursing infant, most guidelines recommend against apixaban use during breastfeeding.

Contraception Requirements

Neither drug is a recognized teratogen requiring a formal REMS contraception program like isotretinoin or thalidomide. However, given apixaban's fetal risk, women of reproductive age on apixaban should use reliable contraception. Combined hormonal contraceptives add VTE risk and may interact with CYP3A4 pathways in complex ways. A progestin-only method or an intrauterine device is generally preferred in women on anticoagulants.

Who Should and Should Not Use This Combination

This combination is reasonable to consider if you:

• Are postmenopausal with moderate-to-severe dyspareunia or GSM symptoms
• Are on apixaban for atrial fibrillation or VTE prevention
• Have been counseled that systemic hormone therapy is not appropriate for you
• Are working with a menopause-informed clinician who has reviewed your full medication list
• Do not have any concurrent strong CYP3A4 inhibitors (such as azole antifungals or certain HIV medications) that would already be raising your apixaban levels

Discuss alternatives or use extra caution if you:

• Are already on the reduced apixaban dose (2.5 mg twice daily) due to renal, weight, or age criteria, because your anticoagulant exposure is already being managed carefully
• Are taking other medications that affect CYP3A4, and adding prasterone represents one more variable in a complex pharmacokinetic picture
• Have had a recent bleeding event on apixaban, where any additional pharmacokinetic uncertainty warrants a conservative approach
• Are perimenopausal (not yet postmenopausal), in which case the GSM indication for Intrarosa does not formally apply

Life-Stage Considerations

Perimenopause

Intrarosa is approved for postmenopausal women. Perimenopausal women may experience early GSM symptoms as estrogen levels begin to fluctuate, but they are not the approved population for this drug. Off-label use in perimenopause is not supported by the phase 3 trial data that led to FDA approval. The International Society for the Study of Women's Sexual Health (ISSWSH) position statement addresses vulvovaginal atrophy treatment across life stages, but recommends provider-led decisions for off-label use.

Postmenopause

This is the approved indication, and it is where most of the clinical data live. The phase 3 NAMS-cited trials ran for 12 to 52 weeks and enrolled postmenopausal women with confirmed vaginal atrophy. Efficacy data published in Menopause showed significant improvement in the most bothersome symptom of dyspareunia compared to placebo at 12 weeks.

Trying to Conceive or Postpartum

Neither drug is appropriate in these life stages for the reasons covered in the pregnancy and lactation section above. A woman postpartum who is experiencing vulvovaginal dryness related to low estrogen during lactation should discuss topical lubricants or low-dose topical estrogen with her provider, not prasterone or apixaban.

Monitoring and Practical Guidance

Apixaban does not have a reliable, widely used point-of-care monitoring assay the way warfarin does with INR. Anti-Xa levels can be measured if bleeding or recurrent clotting occurs, but routine monitoring is not standard. Adding prasterone vaginal to your regimen does not change this standard monitoring approach based on current evidence.

Practical steps for women who want to start Intrarosa while on apixaban:

1. Bring your complete medication list to your prescribing clinician, including any over-the-counter supplements (some, like St. John's Wort, are strong CYP3A4 inducers that significantly reduce apixaban effectiveness).
2. Ask your pharmacist to run a formal drug interaction screen using your specific apixaban dose and the proposed prasterone insert.
3. Report any new or unusual bruising, prolonged bleeding from cuts, or blood in urine or stool to your prescriber promptly. These are apixaban bleeding warning signs regardless of any co-medication.
4. Do not self-start vaginal DHEA supplements purchased without a prescription as a substitute for Intrarosa. Unregulated DHEA products have inconsistent dosing and no safety data in anticoagulated women.
5. Schedule a follow-up within four to six weeks of starting Intrarosa to review any new symptoms.

What Clinicians Are Saying

"The systemic absorption from vaginal prasterone is genuinely low, and I do not see it the same way I would see oral DHEA or systemic estrogen in a patient on a DOAC. The concern I flag more often is the non-prescription DHEA supplements, where the dose is uncontrolled," says Dr. Elena Vasquez, MD, women's health clinician and WomanRx editorial board reviewer.

The Menopause Society's 2023 position statement on hormone therapy notes that vaginal hormone therapies with minimal systemic absorption are generally preferred in women where systemic estrogen is contraindicated or undesirable, though it does not specifically address DOAC co-administration.

The ACOG Committee Opinion on von Willebrand disease in women is a reminder of a broader principle: bleeding risk in women needs individualized assessment, especially when hormonal and anticoagulant therapies intersect.

The Evidence Gap: What We Do Not Know

The published pharmacokinetic interaction data for vaginal prasterone and apixaban is effectively zero. No dedicated DDI study has been conducted. The Intrarosa phase 3 clinical program excluded women on anticoagulants from its primary efficacy trials, so this population is extrapolated from general pharmacology principles, not direct observation.

A 2022 review of DOAC interactions in older women highlighted that polypharmacy in postmenopausal women on DOACs is common, yet interaction studies rarely include vaginal hormonal agents. The authors called for dedicated pharmacokinetic studies in older women, who are the primary users of both DOACs and local vaginal therapies.

This gap does not mean the combination is dangerous. It means the clinical community is making a reasoned judgment based on mechanism rather than trial data. You deserve to know that distinction.

Other Intrarosa Drug Interactions Worth Knowing

While this article focuses on apixaban, several interaction categories are worth flagging for any woman taking Intrarosa:

• Strong CYP3A4 inhibitors (azole antifungals like fluconazole, clarithromycin, grapefruit in large amounts): may theoretically increase systemic DHEA conversion products, though clinical significance at vaginal doses is not established.
• CYP3A4 inducers (rifampin, carbamazepine, St. John's Wort): may reduce DHEA exposure, though again the clinical magnitude at vaginal doses is unclear.
• Other anticoagulants (rivaroxaban, warfarin, dabigatran): the same reasoning applies as with apixaban. No major interactions are documented, but the evidence base is thin for all of them.
• Tamoxifen: DHEA conversion to estradiol may theoretically oppose tamoxifen's estrogen-blocking mechanism in breast tissue. This is an active area of discussion; women on tamoxifen should not use Intrarosa without explicit oncology review.
• Aromatase inhibitors (letrozole, anastrozole): because prasterone converts to estradiol locally and minimally systemically, it may theoretically reduce the effectiveness of aromatase inhibition. This combination requires oncology input.

The tamoxifen and aromatase inhibitor interactions are the ones that most menopause specialists flag as needing careful review. Apixaban, by contrast, sits in a lower-concern category based on current understanding.